SCHEMBL1915928

SCHEMBL1915928

CC(C)C[C@H](CC(=O)OC(C)(C)C)C(=O)O

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC1A3 P43003 1/20 0.44
SLC1A2 P43004 1/20 0.44
MME P08473 4/20 0.44
CPA1 P15085 1/20 0.42
CYP2D6 P10635 1/20 0.41
MEN1 O00255 1/20 0.41
GAA P10253 1/20 0.41
KMT2A Q03164 1/20 0.41
LAP3 P28838 2/20 0.38
CTSL P07711 1/20 0.38
CTSB P07858 1/20 0.38
CTSS P25774 1/20 0.38
CTSK P43235 1/20 0.38
ANPEP P15144 1/20 0.38
HDAC3 O15379 1/20 0.37
HDAC1 Q13547 1/20 0.37
HDAC2 Q92769 1/20 0.37
HDAC8 Q9BY41 1/20 0.37
HDAC6 Q9UBN7 1/20 0.37
RNPEP Q9H4A4 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4633094 1.00 SLC1A3 (0.44) SLC1A3SLC1A2MMECPA1CYP2D6
SCHEMBL1705392 1.00 SLC1A3 (0.44) SLC1A3SLC1A2MMECPA1CYP2D6
Methane SCHEMBL8795616 0.98 SLC1A3 (0.43) SLC1A3SLC1A2MMECPA1CYP2D6
SCHEMBL4839844 0.86 MEN1 (0.47) CYP2D6MEN1GAAKMT2AHDAC3
SCHEMBL8348140 0.86 CYP2D6 (0.43) SLC1A3SLC1A2MMECYP2D6MEN1
SCHEMBL20054394 0.85 KISS1R (0.43) CYP2D6CTSLCTSBCTSSCTSK
SCHEMBL15116513 0.85 KISS1R (0.43) CYP2D6CTSLCTSBCTSSCTSK
SCHEMBL27506606 0.84 CYP2D6 (0.39) SLC1A3SLC1A2MMECYP2D6MEN1
SCHEMBL1199791 0.84 CYP2D6 (0.39) SLC1A3SLC1A2MMECYP2D6MEN1
SCHEMBL15113889 0.84 CYP2D6 (0.41) SLC1A3SLC1A2CYP2D6CTSLCTSB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 164 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180222858-A1 DERIVATIVES OF DOLASTATIN 10 AND AURISTATINS PIERRE FABRE MEDICAMENT (FR) 2018-08-09 US disclosed
US-10022418-B2 Compositions and methods for treating beta-amyloid related diseases AMERICAN LIFE SCIENCE PHARMACEUTICALS, INC. (US) 2018-07-17 US disclosed
US-20180037606-A1 METHODS OF MAKING CARFILZOMIB AND INTERMEDIATES THEREOF APICORE US LLC (US) 2018-02-08 US disclosed
US-9822145-B2 Methods of making carfilzomib and intermediates thereof APICORE US LLC (US) 2017-11-21 US disclosed
US-20170166543-A1 COMPOSITIONS AND METHODS FOR SYNTHESIZING (2S,3S)-TRANS-EPOXYSUCCINYL-L-LEUCYL-AMIDO-3-METHYLBUTANE ETHYL ESTER AMERICAN LIFE SCIENCE PHARMACEUTICALS INC (US) 2017-06-15 US disclosed
US-9586958-B2 Prodrug derivatives of substituted triazolopyridines BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2017-03-07 US disclosed
US-20170057911-A1 SYNTHESIS OF ARYL CYCLOHEXANE CARBOXAMIDE DERIVATIVES USEFUL AS SENSATES IN CONSUMER PRODUCTS PROCTER & GAMBLE (US) 2017-03-02 US disclosed
US-20160340388-A1 METHODS OF MAKING CARFILZOMIB AND INTERMEDIATES THEREOF APICORE US LLC (US) 2016-11-24 US disclosed
US-20160207915-A1 PRODRUG DERIVATIVES OF SUBSTITUTED TRIAZOLOPYRIDINES BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2016-07-21 US disclosed
US-20160115198-A1 METHODS OF MAKING CARFILZOMIB AND INTERMEDIATES THEREOF MYLAN API US LLC 2016-04-28 US disclosed
WO-1994021625-A1 HYDROXAMIC ACID DERIVATIVES AS METALLOPROTEINASE INHIBITORS BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) 1994-09-29 WO disclosed
US-5304604-A Treating diseases involving tissue degradation, promoting wound healing BRITISH BIO-TECHNOLOGY LIMITED (GB) 1994-04-19 US disclosed
US-5304549-A Control or prevention of degenerative joint diseases HOFFMANN-LA ROCHE INC. (US) 1994-04-19 US disclosed
EP-0445206-B1 HYDROXAMIC ACID BASED COLLAGENASE INHIBITORS BRITISH BIO TECHNOLOGY (GB) 1994-03-16 EP disclosed
US-5284828-A Hypotensive agents FUJISAWA PHARMACEUTICAL CO. LTD. (JP) 1994-02-08 US disclosed
WO-1993010144-A1 NEW ENDOTHELIN ANTAGONISTS AND THEIR PREPARATION FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1993-05-27 WO disclosed
EP-0497192-A2 Amino acid derivatives F. HOFFMANN-LA ROCHE AG (CH) 1992-08-05 EP disclosed
EP-0457195-A2 Peptides having endothelin antagonist activity, a process for preparation thereof and pharmaceutical compositions comprising the same FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1991-11-21 EP disclosed
US-4996358-A Control, prevention rheumatic diseases HOFFMANN-LA ROCHE INC. (US) 1991-02-26 US disclosed
WO-1990005716-A1 HYDROXAMIC ACID BASED COLLAGENASE INHIBITORS BRITISH BIO-TECHNOLOGY LIMITED (GB) 1990-05-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160207915-A1 PRODRUG DERIVATIVES OF SUBSTITUTED TRIAZOLOPYRIDINES TK1, PNKP, MPST SLC1A3 2510/4885SLC1A2 3076/4885MME 1962/4885
US-20160340388-A1 METHODS OF MAKING CARFILZOMIB AND INTERMEDIATES THEREOF PAICS, RCE1, CPSF1 SLC1A3 4832/4885SLC1A2 4875/4885MME 682/4885
US-10022418-B2 Compositions and methods for treating beta-amyloid related diseases APP, BACE1, PTMS SLC1A3 2285/4885SLC1A2 3063/4885MME 212/4885
US-20180222858-A1 DERIVATIVES OF DOLASTATIN 10 AND AURISTATINS NR1H4, HCAR3, VDR SLC1A3 1946/4885SLC1A2 3587/4885MME 3779/4885
US-20180037606-A1 METHODS OF MAKING CARFILZOMIB AND INTERMEDIATES THEREOF PAICS, RCE1, CPSF1 SLC1A3 4832/4885SLC1A2 4875/4885MME 682/4885
US-20170166543-A1 COMPOSITIONS AND METHODS FOR SYNTHESIZING (2S,3S)-TRANS-EPOXYSUCCINYL-L-LEUCYL-AMIDO-3-METHYLBUTANE ETHYL ESTER PTMS, LTA, LPXN SLC1A3 275/4885SLC1A2 735/4885MME 1199/4885
US-20160115198-A1 METHODS OF MAKING CARFILZOMIB AND INTERMEDIATES THEREOF PAICS, RCE1, CPSF1 SLC1A3 4832/4885SLC1A2 4875/4885MME 682/4885
US-20170057911-A1 SYNTHESIS OF ARYL CYCLOHEXANE CARBOXAMIDE DERIVATIVES USEFUL AS SENSATES IN CONSUMER PRODUCTS CUTA, ACMSD, SRM SLC1A3 436/4885SLC1A2 466/4885MME 2959/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.